One target-multiple indications: a call for an integrated common mechanisms strategy.
Ever-increasing research and development costs are putting constant pressure on the pharmaceutical industry to improve their efficiency. Efforts to increase the output of the research pipeline have yielded limited success. Traditionally, maximization of the value of a drug is attempted through life-cycle management, which is initiated late in development, or when the drug is already on the market. Validated targets can be exploited further through development of a follow-up drug, which may offer advantages regarding safety or convenience. In this article, we propose to systematically evaluate the full therapeutic potential of a drug target, proprietary chemical lead structure, or drug candidate as broad and as early as possible and we call this the 'common mechanism' approach.
Common Mechanism Research, Bayer HealthCare AG, D-42096 Wuppertal, Germany. Ulrich.Nielsch@BayerHealthcare.com
Ulrich
U
Nielsch
Stefan
S
Schäfer
Hanno
H
Wild
Andreas
A
Busch
D017598:Efficiency, Organizational; D010600:Pharmacology / Q000191:economics* / Q000379:methods*; D012106:Research / Q000191:economics; D012107:Research Design; D013379:Substrate Specificity